Predicting lung exposure of intramuscular niclosamide as an antiviral agent: Power‐law based pharmacokinetic modeling

Documenti analoghi

• Model‐Informed Optimal Dosing of Anti‐CD47 Antibody Using Target‐Mediated Drug Disposition Model
  di: Seongmee Jeong, et al.
  Pubblicazione: (2025)
• Population pharmacokinetics and exposure‐response analyses for efficacy and safety of upadacitinib in patients with axial spondyloarthritis
  di: Sumit Bhatnagar, et al.
  Pubblicazione: (2024)
• Four‐hour‐delayed 3D‐FLAIR MRIs in patients with acute unilateral peripheral vestibulopathy
  di: Keun‐Tae Kim, et al.
  Pubblicazione: (2024)
• Pharmacokinetic comparison of subcutaneously administered CT‐P13 (biosimilar of infliximab) via autoinjector and pre‐filled syringe in healthy participants
  di: Ye Chan Park, et al.
  Pubblicazione: (2024)
• CXCR5 and TLR4 signals synergistically enhance non‐small cell lung cancer progression
  di: Ji Hye Shin, et al.
  Pubblicazione: (2024)